---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008682"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T16:26:07.434586+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025

## Summary
- Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.
- Breen continues as Executive Chairman and Board member, roles held since January and November 2021.
- Breen is a UK-qualified solicitor and former senior partner at Clyde & Co., advising biotech clients.
- No compensatory terms or changes to existing arrangements disclosed in the filing.

## SEC filing metadata
- accession: 0001641172-25-008682
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/0001641172-25-008682-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008682
- JSON: https://secwatch.observer/filing/0001641172-25-008682.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008682.txt

## Key facts
- Executive change
  Michael Breen was appointed as Chief Executive Officer at GT Biopharma, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000164117225008682/0001641172-25-008682-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.